What the Research Shows About Continuous Glucose Monitoring and Blood Sugar Control

A major review of CGM studies reveals consistent improvements in blood sugar levels and fewer low blood sugar events for people with Type 1 diabetes. Here's what you need to know about how this technology is changing diabetes management.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dmental healthtechnologysupport

Key takeaways

CGM use is linked to meaningful reductions in HbA1c (a measure of average blood sugar over time), with improvements ranging from 0.4% to 1.5% across studies
People using CGM experienced substantially fewer hypoglycemic (low blood sugar) events, with one major trial reporting a 72% reduction
The greatest benefits were seen in people who started with higher baseline HbA1c levels
Multiple CGM platforms—including Dexcom, Medtronic, and FreeStyle Libre—showed positive outcomes across different age groups

Why CGM Research Matters

Type 1 diabetes requires constant attention to blood sugar levels. Even with the best efforts and modern medications, many people struggle to reach their target blood sugar ranges. Continuous glucose monitoring (CGM) is a wearable technology that tracks glucose levels throughout the day and night, offering real-time data that wasn't available before.

A comprehensive review of research published in Archives of Internal Medicine Research examined studies on how CGM affects diabetes outcomes. The researchers looked at randomized controlled trials, real-world data, and studies involving people of all ages—children, adults, and older adults—to understand what CGM can actually deliver.

What the Data Shows About Blood Sugar Control

Across multiple studies, CGM use was consistently linked to improvements in blood sugar control. People using CGM saw their HbA1c drop by 0.4% to 1.5%, depending on the study. While these numbers might sound small, even a 0.5% reduction in HbA1c is meaningful for reducing long-term complications.

The research also found that people who benefited most were those who started with higher HbA1c levels—meaning CGM appeared most powerful for people whose diabetes was harder to control at baseline.

A Major Finding: Fewer Low Blood Sugar Events

One of the most significant findings involved low blood sugar (hypoglycemic) events. The HypoDE trial, highlighted in the review, reported a 72% reduction in hypoglycemic episodes among CGM users. This is important because low blood sugar is both a daily concern for many people with Type 1 diabetes and a serious safety issue.

Reducing these events means fewer emergency situations, better quality of life, and reduced anxiety about nighttime lows or unexpected dips during daily activities.

What This Means for CGM Users

This research examined three major commercial CGM systems: Dexcom, Medtronic, and FreeStyle Libre. Benefits were observed across these different platforms and in diverse populations, suggesting that CGM's advantages aren't limited to one brand or age group.

The evidence supports what many people with Type 1 diabetes already experience: CGM provides data that helps with decision-making, reduces dangerous low blood sugar events, and helps achieve better overall blood sugar control. However, technology works best when paired with education, support, and a solid diabetes management plan.

Evidence label

Source: Archives of internal medicine research. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.